ADTX Aditxt Corp: Forward P/S Multiple
Aditxt is expanding its ecosystem through mergers with biotech startups, yet a critical liquidity shortage and mounting debt threaten the holding company's stability. Data from the GURU.Markets terminal provides a calculated forward P/S, where the 1017.10 figure serves as the target level. Meanwhile, patents in immune monitoring provide Aditxt with the potential to monetize intellectual property through clinical ancillary services.
Analytical breakdowns for aditxt.com (ADTX)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- financial results and valuation multiples details:
ADTX - Company Profit|Future Profit Aditxt|ADTX - Market Price to Net Income Ratio|Projected Price to Earnings Aditxt, Inc.|ADTX - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aditxt, Inc.|ADTX - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Aditxt|ADTX - Earnings per share for the trailing year|Quarterly EPS earnings growth aditxt.com|ADTX - Earnings growth in current year|Net earnings per share growth forecast for next year Aditxt
- sales and revenue indicators:
Fundamental company valuation:Aditxt Corp (ADTX)
The efficiency of the Pears platform in monitoring immune rejection during transplants determines the revenue growth rates of Aditxt, which directly impacts the forward P/S as the ratio of market capitalization to expected sales. By analyzing the Aditxt forward P/S chart, an investor assesses the degree of overpayment for future income, utilizing multiple compression to identify entry points into an undervalued asset.
Competing companies
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA - Forward P/S Multiple|PTGX: Forward P/S Multiple|Market Cap to Projected Revenue IMVT|KNSA (Kiniksa) - Forward P/S Multiple|Grifols SA (GRFS) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple ADPT (Adaptive Biotechnologies Corp)|Price to Expected Revenue Ratio CLDX|Aurinia Pharmaceuticals - Forward Price-to-Revenue Multiple|BCRX: Market Cap to Projected Revenue|VERA: Forward Price-to-Revenue Multiple|Dianthus Therapeutics Inc - Price to Expected Revenue Ratio|PHVS: Forward P/S Multiple|AbCellera Corp (ABCL) - Forward P/S Multiple|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|Market Cap to Projected Revenue PGEN (precigen.com)|Forward Price-to-Revenue Multiple PHAR (Pharming Group)|Price to Expected Revenue Ratio NKTR|Upstream Bio Corp - Forward Price-to-Revenue Multiple|ZBIO: Market Cap to Projected Revenue|IMNM - Price-to-Projected Revenue Ratio|Future Price to Revenue GOSS|KALV: Forward P/S Multiple|Septerna, Inc. - Forward Price to Sales|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Forward P/S Multiple Savara Pharma|Price-to-Projected Revenue Ratio Rigel Pharmaceuticals (RIGL)|ANAB (anaptysbio.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|ENGN - Forward Price-to-Revenue Multiple|RAPT Therapeutics, Inc. - Forward P/S Multiple|JBIO - Forward P/S Multiple|ACRS (Aclaris Therapeutics) - Forward Price-to-Revenue Multiple|kyvernatx.com - Forward Price to Sales|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|Cabaletta Bio Inc. (CABA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Ventyx Bio (VTYX)|Forward Price-to-Revenue Multiple Theratechnologies, Inc THTX|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|ELDN - Forward Price-to-Revenue Multiple|AGEN: Forward Price-to-Revenue Multiple|CLYM - Forward P/S Multiple|Zura Bio Limited (ZURA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ATYR|ADAG (Adagene Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ikena Oncology, Inc. IMA|Forward P/S Multiple STTK|Forward P/S Multiple equilliumbio.com (EQ)|Forward P/S Multiple CNTB (Connect Biopharma Holdings Limited)|IMUX: Market Cap to Projected Revenue|Atara Biotherapeutics Inc - Forward P/S Multiple|Market Cap to Expected Sales Ratio InflaRx N.V. IFRX|XFOR (X4 Pharmaceuticals, Inc.) - Forward Price-to-Revenue Multiple|ACET: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple CELU|Market Cap to Projected Revenue INMB (INmune Bio Corporation)|Forward Price-to-Revenue Multiple BRNS (Barinthus Biotherapeutics)|Price to Expected Revenue Ratio KZR|Forward P/S Multiple SABS (SAB Biotherapeutics, Inc.)|Forward P/S Multiple Akari Therapeutics PLC AKTX|Enlivex Therapeutics, Ltd. - Forward P/S Multiple|QTTB (Q32 Bio Inc.) - Market Cap to Projected Revenue|GOVX (GeoVax Labs, Inc.) - Forward Price-to-Revenue Multiple|EDSA: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple IBIO|Market Cap to Projected Revenue CARM (Carisma Tx)|Price-to-Projected Revenue Ratio XTL Biopharmaceuticals, Ltd. (XTLB)|BOLT: Future Price to Revenue|Forward P/S Multiple HCWB (HCW Biologics)|Forward Price to Sales APVO|AIM ImmunoTech - Forward P/S Multiple|GRI - Forward P/S Multiple|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Vyome Therapeutics - Forward Price to Sales|Price-to-Projected Revenue Ratio Revelation Biosciences|Forward Price-to-Revenue Multiple indaptusrx.com (INDP)|Forward P/S Multiple SCNI|Forward P/S Multiple calcimedica.com (CALI)|Affimed N.V. - Forward Price-to-Revenue Multiple|Forward Price to Sales ALLK|HOOKIPA - Forward P/S Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Ocean Biomedical Inc|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward Price-to-Revenue Multiple Third Harmonic Bio Inc (THRD)
